Assembly Bio reports Q2 net loss $10.2M; ABI-6250 shows 4-day half-life supporting once-daily dosing

ASSEMBLY BIOSCIENCES, INC.

2025-Q2 EPS reported -$2.51 revenue$19,045,000

Net loss $10.2M ($1.33/share) vs $11.2M ($1.98/share) in Q2 2024; revenue from Gilead collaboration $9.6M.
Cash $75.0M as of June 30, 2025, projected to fund operations into mid-2026.
ABI-6250 Phase 1a interim: mean half-life ~4 days supports once-daily oral dosing; dose-dependent bile acid elevations show NTCP target engagement.
Safety: all AEs grade 1-2; one grade 2 ALT elevation at highest single dose (25 mg), self-limited, no serious AEs.
Phase 1b herpes data (ABI-5366, ABI-1179) on track for fall 2025; positive Phase 1b data for ABI-4334 (HBV) reported earlier.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.